Share on StockTwits

Zoetis (NYSE:ZTS) has been given an average recommendation of “Hold” by the six ratings firms that are covering the stock, American Banking News reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $29.80.

Zoetis (NYSE:ZTS) opened at 33.93 on Friday. Zoetis has a one year low of $28.14 and a one year high of $34.01. The stock has a 50-day moving average of $32.71 and a 200-day moving average of $30.97. The company has a market cap of $17.005 billion and a price-to-earnings ratio of 32.02.

The company also recently declared a quarterly dividend, which is scheduled for Tuesday, September 2nd. Investors of record on Wednesday, August 20th will be paid a dividend of $0.072 per share. This represents a $0.29 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Monday, August 18th.

A number of research firms have recently commented on ZTS. Analysts at Jefferies Group cut their price target on shares of Zoetis from $38.00 to $37.00 in a research note on Monday, August 11th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Zoetis in a research note on Wednesday, August 6th. They now have a $34.00 price target on the stock. Finally, analysts at BMO Capital Markets cut their price target on shares of Zoetis from $37.00 to $36.00 in a research note on Wednesday, August 6th.

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.